Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Patent
1996-12-11
1998-11-24
Feisee, Lila
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
514 12, A61K 3818
Patent
active
058403116
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an agent accelerating collagen decomposition and a therapeutic agent for fibrosis disorder. More particularly, the present invention relates to an agent accelerating collagen decomposition and a therapeutic agent for fibrosis disorder comprising HGFs (Hepatocyte Growth Factors) as an active ingredient.
BACKGROUND ART
Fibrosis is a disease characterized by the excessive accumulation of a connective tissue component, and one which is a noticeable component in fibrosis is collagen. Accumulation of collagen occurs in a variety of viscera, for example, brings about pulmonary fibrosis in lung and liver fibrosis in liver. Also in skin, for example, the accumulation of collagen brings about disorders such as cutis keloid formation.
In many cases, the net accumulation of collagen in fibrosis is the result of disproportion between factors which bring about decomposition and production of collagen.
Though various medications have been conducted to treat the disorder and sickness of fibrosis, they were mainly for symptomatic therapy for the disorder in general, and were not those which aim at dissolving pathogenesis, namely the disproportion between metabolism factors which regulate decomposition and production of collagen and the other connective tissue component. Therefore, in these therapies, there was no especially effective method in point of tissue repair. For example, though local corticosteroid was used to treat the initial inflammation stage of cutis keloid formation and success was made to a certain extent, such steroid treatment has little or no effect on the latter fibrosis stage such as in case of actual formation of keloid as a result of excessive production of collagen.
As described above, in the prior art, there could not have been discovered a safe and effective method which treats fibrosis disorder of human, inhibits more formation of fibrous tissue and reduces or completely removes the focus of fibrosis previously formed.
The object to be solved by the present invention is to provide an agent accelerating collagen decomposition which can induce the decomposition of a collagen matrix of excessively accumulated connective tissue in tissue and a therapeutic agent useful for treatment of fibrosis disorder.
DISCLOSURE OF THE INVENTION
The present inventors have intensively investigated to solve the object described above. As a result, the inventors found that HGFs have an action to promote the decomposition of collagen and are effective for the treatment of fibrosis disorder based on their action. And thereby the present invention has been completed.
Namely, the present invention is an agent accelerating collagen decomposition containing at least one of HGFs as an active ingredient.
Another invention is a therapeutic agent for fibrosis disorder containing at least one of HGFs as an active ingredient.
Still other inventions are a method for accelerating collagen decomposition comprising administering at least one of HGFs in an effective amount; a method for treating fibrosis disorder comprising administering at least one of HGFs in an effective amount; use of at least one of HGFs for producing an agent accelerating collagen decomposition; and use of at least one of HGFs for producing a therapeutic agent for fibrosis disorder.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a chart which shows medicine-administration schedule in Example 1.
FIG. 2 is a chart which shows medicine-administration schedule in Test A of Example 2.
FIG. 3 is a chart which shows medicine-administration schedule in Test B of Example 2.
FIGS. 4A-4C are graphs showing the results of GOT (FIG. 4A), GPT (FIG. 4B) and .gamma.-GTP (FIG. 4C) measurements in Test A of Example 2.
FIGS. 5A-5D are graphs showing the results of GOT (FIG. 5A), GPT (FIG. 5B) and hepaplastin tests (FIG. 5C) and the measurement of liver Hyp (hydroxyproline) (FIG. 5D) content in Test B of Example 2.
FIG. 6 is a graph which shows the survival effect of HGF on a liver fibrosis of rats in Test A of Example 3. In F
REFERENCES:
patent: 5004805 (1991-04-01), Gohda et al.
Shiota et al. Hepatol. 21:106-12, 1995.
Gherardi et al. Proc. Natl. Acad. Sci. 86:5844-48, Aug. 1989.
Shimiyu et al. J. Biochem. 109:14-18, 1991.
Ishiki et al. Hepatol. 16:1227-35, 1992.
Fujise Nobuaki
Nakamura Toshikazu
Namiki Mitsuo
Shiota Akira
Bansal Geetha P.
Feisee Lila
Nakamura Toshikazu
Snow Brand Milk Products Co. Ltd.
Sumitomo Pharmaceuticals Co. Ltd.
LandOfFree
Agent accelerating collagen decomposition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agent accelerating collagen decomposition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent accelerating collagen decomposition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699184